ArticleCureus2025
Autoimmune Hepatitis (AIH) Related to Drug-Induced Liver Injury (DILI) Due to Atorvastatin.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic PCSK9 elevation characterises autoimmune liver disease across sexes.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a rare condition characterized by hepatotoxic damage, identified through the elevation of liver function tests associated with a specific drug. Statins are among the medications linked to DILI, although this association is infrequent. Recently, reports and case series have described a relationship between atorvastatin-induced DILI and autoimmune hepatitis (AIH), two conditions not commonly associated. Because there are no established clinical or diagnostic criteria for this overlap, recognition is complex and relies on the clinical course, a timeline of causality, and the exclusion of alternative diagnoses. This report presents the case of a patient in the seventh decade of life who developed atorvastatin-induced DILI, meeting the diagnostic criteria for AIH. We discuss the therapeutic approach and review the relevant literature on this rare association.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.